Zacks: Geron’s telomerase technology platform represents significant commercial opportunity

Forum rules
- Comments must be civil and on topic
- Back up claims with evidence/reasoning/sources (posting links is allowed)
- No commercials/harassment/spam
Post Reply
Fishermangents
Site Admin
Posts: 531
Joined: Thu Dec 03, 2015 3:39 pm

Zacks: Geron’s telomerase technology platform represents significant commercial opportunity

Post by Fishermangents » Wed Dec 09, 2015 2:32 pm

Zacks, 8 Dec 2015:

Geron’s telomerase technology platform represents significant commercial opportunity. The successful development of products that target telomeres could very well change the treatment paradigm for several diseases including oncology, which represents significant commercial potential.
Geron is developing anti-cancer therapies based on telomerase inhibitors. Although telomerase is expressed in nearly all cancer cells, it is not expressed in most normal cells. This means that drugs and biologics that attack cancer cells by targeting telomerase may leave most other cells unaffected. Such drugs could have fewer side effects compared to conventional chemotherapeutic agents which usually affect both cancer and non-cancer cells. The successful development of anti-cancer therapies would open up huge commercial opportunities for the company.
As telomerase expression has been found to be present in about 90% of biopsies taken from a broad range of human cancers, telomerase-based drugs could overcome the limitations seen with current cancer therapies and could be broadly applicable and highly specific drug treatments for cancer. Geron’s telomerase inhibitor, imetelstat, has the potential to be developed for the treatment of hematologic myeloid malignancies like MF (phase II study ongoing), MDS (phase II study to commence by year end) and AML. Imetelstat has orphan drug status in the U.S. for the MF indication.

(from SA, no link unfortunately)

Post Reply